Axial spondyloarthritis (axSpA) is a chronic inflammatory disease causes inflammation and pain in the spine and sacroiliac joints. The disease can cause back pain, stiffness, fatigue, and swelling in the involved areas. Biologics such as anti-TNF drugs like Humira, Enbrel, and Cosentyx are effective treatment options for axSpA that can help reduce inflammation and symptoms. Nonsteroidal anti-inflammatory drugs (NSAIDs) are first-line medications that help relieve pain and stiffness.

The axial spondyloarthritis (axSpA) treatment market is estimated to be valued at USD 6.02 billion in 2024 and is expected to reach USD 10 billion by 2031, growing at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031.

The primary driver propelling the Axial Spondyloarthritis (AXSPA) Treatment Market growth is the rising prevalence of the disease. Genetics plays a significant role in the development of axSpA, and it commonly affects individuals between the ages of 18 to 50. Environmental triggers like gastrointestinal and urinary infections can also heighten the risk of axSpA. With improved awareness and diagnostic assessments, more people are being diagnosed early, thereby requiring treatment interventions. This rising disease prevalence will augment demand for therapeutic drugs in the forecast period.

Get More Insights On- Axial Spondyloarthritis (AXSPA) Treatment Market

Get This Report in Japanese Language: 軸性脊椎関節炎治療市場

Get This Report in Korean Language: 축성 척추관절염치료 시장